Lung Cancer Trials Ask AI to find trials
RecruitingPhase 1NCT05245500
Official study title

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Study summary

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedMRTX1719

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Mesothelioma · Early-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 2, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1

Interventional

Where is it offered?25 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Bristol-Myers Squibb
Interventions being studied
Drug: MRTX1719
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→Mesothelioma→
Disease setting
Early-stage or resectable→Metastatic or stage IV→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue.
  • Unresectable or metastatic disease.
  • Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible.
  • Age ≥ 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate organ function.
Reasons someone may not be able to joinExclusion criteria
  • Prior treatment with a PRMT5 or MAT2A inhibitor therapy.
  • Active brain metastases or carcinomatous meningitis.
  • History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.
  • Major surgery within 4 weeks of first dose of study treatment.
  • History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications.
  • Cardiac abnormalities.
  • Other protocol-defined Inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Mayo ClinicPhoenix, Arizona
  • Rocky Mountain Cancer Centers, LLP - OncologyLone Tree, Colorado
  • Mayo ClinicJacksonville, Florida
  • Sarah Cannon Research Institute at Florida Cancer SpecialistsOrlando, Florida
  • Local Institution - 124Chicago, Illinois
  • Dana-Farber Cancer InstituteBrookline, Massachusetts
  • The Cancer & Hematology CentersGrand Rapids, Michigan
  • Cancer and Hematology Centers of Western MichiganNorton Shores, Michigan
  • Mayo ClinicRochester, Minnesota
  • Rutgers Cancer Institute of New JerseyNew Brunswick, New Jersey
  • Perlmutter Cancer Center at NYU Langone Hospital Long IslandMineola, New York
  • David H Koch, Memorial Sloan Kettering Cancer CenterNew York, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 2, 2026. Always confirm current availability with the study team.

View original record ↗